C. Page (London, United Kingdom), M. Cazzola (Naples, Italy)
GM-CSF is a key pathogenic mediator in experimental COPD
R. Vlahos, S. Bozinovski, L. B. Irving, J. A. Hamilton, G. P. Anderson (Parkville, Australia)
|  |
Employing flow cytometric assays of human whole blood neutrophil and monocyte CD11b upregulation and shape change to assess a chemokine receptor (CXCR2) antagonist
G. C. Nicholson, D. C. Carpenter, R. M. Tal-Singer, R. C. Tennant, P. J. Barnes, T. T. Hansel (London, United Kingdom; Philadelphia, United States Of America)
|  |
Expression of adenosine receptors in the peripheral lung from COPD patients
K. Varani, G. Caramori, P. Casolari, C. Pancaldi, F. Vincenzi, I. M. Adcock, K. F. Chung, P. J. Barnes, G. Cavallesco, G. Azzena, P. A. Borea, A. Papi (Ferrara, Italy; London, United Kingdom)
| |
N-acetylcysteine reduces 8-isoprostane levels in exhaled breath condensate and serum of COPD patients
E. Bucchioni, T. Cappelletti, G. Pozzoli, S. Galbiati, B. Dallari, L. Allegra (Milan, Italy)
| |
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Y. To, S. Kharitonov, I. M. Adcock, P. J. Barnes, K. Ito (London, United Kingdom)
| |
Cigarette smoke-induced IL-8 production by human monocyte-derived macrophages: synergistic inhibition by fluticasone and salmeterol
H. Sarir, E. Mortaz, F. Nijkamp, G. Folkerts (Utrecht, Netherlands)
| |
Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD
K. F. Rabe, W. Timmer, A. Sagriotis, K. Viel (Leiden, Netherlands; Biberach, Germany)
| |
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD
M. D‘Amato, F. Andò, P. Santus, P. Ruggeri, F. Di Marco, M. Cazzola (Naples, Messina, Milan, Italy)
| |